Palatin Technologies, Inc. (PTN) Stock Analysis & Investment Frameworks
Palatin Technologies, Inc. (PTN) stock analysis on Invetso. Review Palatin Technologies, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Palatin Technologies, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Palatin Technologies, Inc. Key Financial Metrics
- Market Cap: $10.72M
- Revenue: $13.19M
- ROE: -115.00%
- ROIC: -125.44%
- Dividend Yield: N/A
About Palatin Technologies, Inc.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Palatin Technologies, Inc. Investment Frameworks
Invetso analyzes Palatin Technologies, Inc. (PTN) across the following frameworks:
- Palatin Technologies, Inc. 10Y Growth Potential
- Palatin Technologies, Inc. Scenario Analysis
- Palatin Technologies, Inc. Risks & Opportunities
- Palatin Technologies, Inc. Economic Moat
- Palatin Technologies, Inc. Business Model
- Palatin Technologies, Inc. Management
- Palatin Technologies, Inc. SWOT Analysis
- Palatin Technologies, Inc. Porter's 5 Forces
- Palatin Technologies, Inc. PESTLE Analysis
- Palatin Technologies, Inc. ESG Analysis